But, end of the week and all seem sorted out. Orchid finally announced a so called business alliance (or a silent upcoming merger!) with Malvinder Singh’s Ranbaxy, while the Burman 
family sold off its entire stake (around 65%) in Dabur Pharma to Fresenius Kabi. The German group further raised its holding to 73.3% and even made an open offer for an additional 20% in an attempt to engulf whole of it. Looks like the predator is not satisfied with just a pound of flesh, but wants the entire roast. So, is it that the long due consolidation in the Rs.320 billion Indian pharma industry has finally arrived? Or is it that the global & domestic predators are conditioning themselves before the final hunt, which they anyway have been doing since long?
Certainly, the Indian pharma players, who have been among the frontrunners moving in for a kill on the global arena, more so just after India entering the new product patent regime, once again seem standing at an influx of an acquisition drive, but this time at the domestic front. And according to industry experts, the recent slew of happenings could definitely provide a spring board to trigger this much needed and long due consolidation in the domestic market. “The Indian market, which is highly fragmented, is all ripe for consolidation. However, currently the valuations demanded by the companies are on the higher side and are a major deterrent to the same. But, going ahead in the next 1-2 years, the momentum could gather further pace, as these companies would look out to consolidate their presence in the Indian markets,” Sarabjit Kour Nangra, VP Research, Angel Broking tells 4Ps B&M. Even Ranjit Shahani, Vice Chairman & MD, Novartis India holds the same view when it comes to M&As. “We can already see some consolidation happening in this space with many organisations wanting to scale up their operations, which will enable them to meet increasingly diverse challenges,” he shares with us.
For Complete IIPM Article, Click on IIPM Article
Source : IIPM Editorial, 2008
family sold off its entire stake (around 65%) in Dabur Pharma to Fresenius Kabi. The German group further raised its holding to 73.3% and even made an open offer for an additional 20% in an attempt to engulf whole of it. Looks like the predator is not satisfied with just a pound of flesh, but wants the entire roast. So, is it that the long due consolidation in the Rs.320 billion Indian pharma industry has finally arrived? Or is it that the global & domestic predators are conditioning themselves before the final hunt, which they anyway have been doing since long?Certainly, the Indian pharma players, who have been among the frontrunners moving in for a kill on the global arena, more so just after India entering the new product patent regime, once again seem standing at an influx of an acquisition drive, but this time at the domestic front. And according to industry experts, the recent slew of happenings could definitely provide a spring board to trigger this much needed and long due consolidation in the domestic market. “The Indian market, which is highly fragmented, is all ripe for consolidation. However, currently the valuations demanded by the companies are on the higher side and are a major deterrent to the same. But, going ahead in the next 1-2 years, the momentum could gather further pace, as these companies would look out to consolidate their presence in the Indian markets,” Sarabjit Kour Nangra, VP Research, Angel Broking tells 4Ps B&M. Even Ranjit Shahani, Vice Chairman & MD, Novartis India holds the same view when it comes to M&As. “We can already see some consolidation happening in this space with many organisations wanting to scale up their operations, which will enable them to meet increasingly diverse challenges,” he shares with us.
For Complete IIPM Article, Click on IIPM Article
Source : IIPM Editorial, 2008
An IIPM and Professor Arindam Chaudhuri (Renowned Management Guru and Economist) Initiative
Read these article :-
ZEE BUSINESS BEST B SCHOOL SURVEY
B-schooled in India, Placed Abroad (Print Version)
IIPM in Financial times (Print Version)
IIPM makes business education truly global (Print Version)
The Indian Institute of Planning and Management (IIPM)
IIPM Campus
2 comments:
IIPM Rankings is one of the best in MBA (Full time Programme in National Economic Planning and Entrepreneurship) business school ranking
iipm also ranks one in global exposure according to zeebiz.com online survey
Post a Comment